Company profile: Bicara Therapeutics
1.1 - Company Overview
Company description
- Provider of dual-action cancer therapies combining targeted treatments with tumor modulators. Offers BCA101, a dual-action bifunctional antibody that inhibits EGFR and disables TGF-β at the tumor site, in clinical trials across multiple cancer types; and BCA356, a bispecific antibody targeting CAIX conjugated to attenuated IL-12, with pre-clinical efficacy and potential for limited systemic toxicity.
Products and services
- Dual-Action Cancer Therapy Development: Bicara Therapeutics architects dual-action oncology products that combine targeted treatments with tumor modulators for enhanced impact on tumors
- BCA101: A clinical-stage bifunctional antibody engineered to inhibit EGFR and disable TGF-β directly at the tumor site, currently in clinical trials across multiple cancer indications
- BCA356: A pre-clinical bispecific antibody targeting tumor antigen CAIX conjugated to attenuated IL-12, demonstrating pre-clinical efficacy with potential for limited systemic toxicity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bicara Therapeutics
ArcherDX
HQ: United States
Website
- Description: Provider of NGS-based assay solutions advancing molecular pathology, using proprietary Anchored Multiplex PCR (AMP) chemistry and Archer Analysis software to detect genetic mutations for solid tumor, blood cancer, and genetic disease research. Offers VARIANTPlex DNA panels, FUSIONPlex RNA panels, LIQUIDPlex ctDNA panels, IMMUNOVerse immune profiling assays, and an Assay Marketplace for custom NGS panels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArcherDX company profile →
Fabrus
HQ: United States
Website
- Description: Provider of functional therapeutic monoclonal antibody discovery and development targeting challenging cell surface proteins, including GPCRs and ion channels, supported by a unique antibody discovery platform and multiple preclinical lead candidates against important cancer targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fabrus company profile →
EpiCapture
HQ: Ireland
Website
- Description: Provider of accurate, non-invasive urine tests to detect aggressive cancers, focused on improving cancer patient care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EpiCapture company profile →
Ceptaris
HQ: United States
Website
- Description: Provider of a proprietary gel formulation of mechlorethamine hydrochloride under development for the treatment of early-stage (stages I–IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL); if approved, it would be the first topical treatment for this indication.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ceptaris company profile →
Flare Therapeutics
HQ: United States
Website
- Description: Provider of precision therapies by targeting transcription factors, including FX-909, a first-in-class small molecule PPARG inhibitor in Phase 1 for advanced solid malignancies such as advanced urothelial carcinoma. Offers a discovery engine and a pipeline of TF-targeted drug programs, with switch site identification, ligandability, and pharmacology capabilities, initially focused on precision oncology and expanding to metabolic, neurology, immunology/inflammation, and rare genetic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Flare Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bicara Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bicara Therapeutics
2.2 - Growth funds investing in similar companies to Bicara Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bicara Therapeutics
4.2 - Public trading comparable groups for Bicara Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →